On Monday, PTC Therapeutics received a positive adjustment to its Relative Strength (RS) Rating, from 90 to 93.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 at the beginning of a new price run.
Here Are 3 Keys For Successful Stock Investing
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buy zone in heavy volume.
PTC Therapeutics posted 0% EPS growth last quarter. Sales gains came in at -31%. The next quarterly numbers are expected on or around Apr. 24.
PTC Therapeutics holds the No. 74 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
